DB:GHDN

Stock Analysis Report

Brainstorm Cell Therapeutics

Executive Summary

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases.


Snowflake Analysis

Moderate growth potential with worrying balance sheet.

Share Price & News

How has Brainstorm Cell Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GHDN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.9%

GHDN

5.1%

DE Biotechs

-2.7%

DE Market


1 Year Return

9.9%

GHDN

-10.6%

DE Biotechs

-20.4%

DE Market

Return vs Industry: GHDN exceeded the German Biotechs industry which returned -10.6% over the past year.

Return vs Market: GHDN exceeded the German Market which returned -20.4% over the past year.


Shareholder returns

GHDNIndustryMarket
7 Day-1.9%5.1%-2.7%
30 Day-41.1%-5.4%-18.4%
90 Day9.6%-22.4%-26.7%
1 Year9.9%9.9%-10.4%-10.6%-18.1%-20.4%
3 Yearn/a16.0%14.8%-19.1%-25.9%
5 Yearn/a-6.3%-8.8%-19.5%-30.4%

Price Volatility Vs. Market

How volatile is Brainstorm Cell Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Brainstorm Cell Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Brainstorm Cell Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Brainstorm Cell Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Brainstorm Cell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

58.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GHDN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: GHDN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GHDN's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if GHDN's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if GHDN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GHDN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Brainstorm Cell Therapeutics performed over the past 5 years?

-21.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GHDN is currently unprofitable.

Growing Profit Margin: GHDN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GHDN is unprofitable, and losses have increased over the past 5 years at a rate of -21% per year.

Accelerating Growth: Unable to compare GHDN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GHDN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: GHDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Brainstorm Cell Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GHDN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: GHDN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: GHDN is debt free.

Reducing Debt: GHDN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: GHDN has a high level of physical assets or inventory.

Debt Coverage by Assets: GHDN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GHDN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GHDN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -15.8% each year


Next Steps

Dividend

What is Brainstorm Cell Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GHDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GHDN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GHDN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GHDN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GHDN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Chaim Lebovits (48yo)

4.58s

Tenure

US$1,056,276

Compensation

Mr. Chaim Lebovits has been the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and as its President since July 3, 2007. Mr. Lebovits serves as the Chief Executive Off ...


CEO Compensation Analysis

Compensation vs Market: Chaim's total compensation ($USD1.06M) is above average for companies of similar size in the German market ($USD427.28K).

Compensation vs Earnings: Chaim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Chaim Lebovits
President & CEO4.58yrsUS$1.06m0.36% $397.0k
Irit Arbel
Founder & Vice Chair of the Board0.083yrUS$84.37k0.59% $661.2k
Preetam Shah
Executive VP0.58yrUS$882.92k0.14% $155.3k
Ralph Kern
COO & Chief Medical Officer3.08yrsUS$852.15k0.58% $643.0k
Uri Yablonka
Executive VP5.83yrsUS$44.40k0.029% $32.0k
Yael Gothelf
Vice President of Scientific & Regulatory Affairsno datano datano data
Daniel Offen
Chief Scientific Advisorno datano datano data
Arturo Araya
Chief Commercial Officer1.58yrsUS$20.44k0.033% $36.5k
Susan Ward
Head of Clinical Operations1.83yrsno datano data
Thomas Rosedale
Secretaryno datano datano data

2.5yrs

Average Tenure

48yo

Average Age

Experienced Management: GHDN's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Irit Arbel
Founder & Vice Chair of the Board0.083yrUS$84.37k0.59% $661.2k
Uri Yablonka
Executive VP5.83yrsUS$44.40k0.029% $32.0k
Jacob Frenkel
Chairman of the Board0.083yrno datano data
Harvey Krueger
Member of Business Advisory Board12.67yrsno datano data
Andrew Card
Member of Business Advisory Board9.08yrsno datano data
Malcolm Taub
Independent Director11.08yrsUS$46.68k0.20% $226.3k
Rasheda Ali
Member of Business Advisory Board12.5yrsno datano data
Jerold Chun
Chairman of Scientific Advisory Board2.08yrsno datano data
June Almenoff
Independent Director3.17yrsUS$37.78k0.035% $38.9k
Anthony Polverino
Independent Director2.17yrsUS$30.00k0.060% $67.3k

4.5yrs

Average Tenure

66.5yo

Average Age

Experienced Board: GHDN's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

Brainstorm Cell Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Brainstorm Cell Therapeutics Inc.
  • Ticker: GHDN
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$121.711m
  • Listing Market Cap: US$111.305m
  • Shares outstanding: 26.23m
  • Website: https://www.brainstorm-cell.com

Number of Employees


Location

  • Brainstorm Cell Therapeutics Inc.
  • 1325 Avenue of Americas
  • 28th Floor
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2003
GHDNDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2003

Biography

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 20:42
End of Day Share Price2020/04/01 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.